Cargando…
Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design
Prostate cancer is the second most diagnosed cancer in men and current treatment of advanced prostate cancer is ineffective. Immunotherapy has emerged as a promising treatment option for metastatic prostate cancer but its clinical application is still in the early stages of development. In order to...
Autores principales: | Doonan, Bently P, Haque, Azizul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721631/ https://www.ncbi.nlm.nih.gov/pubmed/26807308 http://dx.doi.org/10.4172/2155-9899.1000351 |
Ejemplares similares
-
Peptide Modification Diminishes HLA Class II-restricted CD4(+) T Cell Recognition of Prostate Cancer Cells
por: Doonan, Bently P., et al.
Publicado: (2022) -
GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition
por: Hathaway-Schrader, Jessica D., et al.
Publicado: (2022) -
Insights into the Role of GILT in HLA Class II Antigen Processing and Presentation by Melanoma
por: Norton, Duncan L., et al.
Publicado: (2009) -
Multiple Defects Impair the HLA Class II Antigen Presentation Capacity of Burkitt Lymphoma
por: God, Jason M., et al.
Publicado: (2016) -
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
por: Dillard, Pierre, et al.
Publicado: (2021)